A new look at old problems: Ovarian function suppression in the real world

There is concern that the addition of ovarian function suppression to the endocrine treatment of premenopausal patients with breast cancer will increase nonadherence to treatment in this population. Although nonadherence to oral endocrine therapy was fairly high in the first year in this study, it was not worse when it was combined with endocrine therapy.

Automated summary

Although there is concern that adding ovarian function suppression to endocrine treatment in premenopausal breast cancer patients may increase nonadherence to treatment, a study showed that the combination did not worsen adherence rates compared to oral endocrine therapy alone.